Navigation Links
MRI contrast agents change stem cell proliferation
Date:11/1/2010

Tampa, Fla. (Nov. 01, 2010) When researchers tested three different labeling agents on three different stem cell populations to determine what effect the labeling agents had on stem cell phenotype, biological behavior and migration abilities, they found changes in stem cell proliferation depending on the type of contrast agent used.

The team of researchers from Belgium and Spain tested USPIO (ultra small superparamagnetic iron oxide) contrast agents Resovist , Endorem and Sinerem on mouse embryonic stem cells (mESC), rat multipotent adult progenitor cells (rMAPC) and mouse mensenchymal stem cells (mMSC). Their study is published in the current issue of Cell Transplantation (19:8), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

The researchers found the labeling efficiency with each of the (U)SPIOs varied significantly when different stem cell populations were compared.

"This means that labeling methods will likely need to be optimized for every cell type," said Dr. Crabbe. "Over time we saw a dilution of (U)SPIOs and a decrease of iron in the cells."

Non-invasive imaging plays an important post-transplantation role in stem cell research, but questions regarding whether the contrast agents used to track transplanted stem cells in vivo via MRI have an impact on the cells had largely gone unanswered until this study.

On the issue of whether (U)SPIO labeling has a biological affects on cells, the researchers discovered "no significant alterations" in cell phenotypes and that the label "does not significantly alter stem cell differentiation."

"Sinerem decreased proliferation of mMSC while both Sinerem and Endorem affected the proliferation rate of rMAPC, although prolonged culture, until seven days, resulted in restoration of the proliferation rate," noted Dr. Crabbe. "We also found that higher concentrations of Sinerem and Endorem were needed for cell labeling to achieve similar MRI detectability."

The researchers concluded that it will be necessary to evaluate the efficiency of cell labeling for every new contrast agent combination aimed at being followed in vivo by MRI. Also, the effect on biological behavior of cells should be examined. They noted that their results were limited to examining the effects of labeling on proliferation, not differentiation.

"Although labeling of stem cells with MRI is promising, there are some limitations," concluded Dr. Crabbe. "More optimal particles are needed that can be taken up without the need of potentially toxic agents. Also, there is the problem of particle dilution over time as cells divide. When grafted cells continue to proliferate, loss of signal occurs."

According to Dr. Julio Voltarelli, professor of clinical medicine and clinical immunology at the University of Sao Pulo, Brazil and section editor for Cell Transplantation there has been a knowledge gap regarding the survival and distribution of stem cell populations used for in vivo therapy.

"Many studies have tried to close this gap by using radioactive or nonradioactive labeling of the cells in order to follow their fate in the organism," said Dr. Voltarelli. "However, this paper demonstrates that such labeling may alter stem cell behavior, such as proliferative potential, and give biased information when compared to nonlabeled cells."


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents
2. Chemists concoct new agents to easily study critical cell proteins
3. Biotech collaboration established to commercialize research reagents
4. Novel antitoxin strategy developed using tagged binding agents
5. Securing biological select agents and toxins will require developing a culture of trust
6. Structure of enzyme against chemical warfare agents determined
7. Chemopreventive agents in black raspberries identified
8. MIT nanotubes sniff out cancer agents in living cells
9. Slight change in wind turbine speed significantly reduces bat mortality
10. Changes in energy R&D needed to combat climate change
11. Universities receive grants to study climate change decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug ... Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( ... expected to deliver therapeutic levels of olanzapine for a period of 3 months., “We ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... 2017 Symic Bio, a biopharmaceutical company focused ... of therapeutics, announced today the completion of enrollment for ... disease. The trial will evaluate the safety and efficacy ... reduction of restenosis following angioplasty. "We,re ... SB-030," said Nathan Bachtell , M.D., Chief Medical ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology: